Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Pancreatic Adenocarcinoma 1PD-L1-selected Solid Tumors 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Follicular 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Unresectable or Metastatic Solid Malignancy 1Advanced Liver Cancers 1

Interventions

Rituximab 90Cyclophosphamide 30Lenalidomide 28Bendamustine Hydrochloride 24Prednisone 20Vincristine 19obinutuzumab 17Doxorubicin 16fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Deoxycholic Acid 9parsaclisib 8Prednisolone 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × Tiragolumab × Clear all
NCT05315713 2024-10-04

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1/2 Terminated
8 enrolled 12 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡